期刊文献+

血栓形成机制及血小板膜糖蛋白ⅡbⅢ/a受体拮抗剂的研究进展 被引量:24

Mechanism of thrombosis and GPⅡb/Ⅲa receptor antagonists:a research progress
下载PDF
导出
摘要 血小板膜糖蛋白(GP)ⅡbⅢ/a与纤维蛋白原的结合是血小板聚集的终末共同途径,因而GPⅡbⅢ/a受体拮抗剂可有效地预防血小板介导的血栓形成。本文对血栓形成的机制以及近年来GPⅡbⅢ/a受体拮抗剂在抗血栓方面的研究进展作一简要综述。 The conjugation of platelet glycoprotein (GP) Ⅱb/Ⅲ a with fibrinogen is the final common pathway of platelet aggregation. GP Ⅱb/Ⅲ a receptor antagonists may be effective in preventing plateletmediated thrombosis. This article reviews the mechanism of thrombosis and the research progress of GP Ⅱb/Ⅲ a receptor antagonists in the anti-thrombotic treatment in recent years.
出处 《国际药学研究杂志》 CAS 2009年第4期268-271,共4页 Journal of International Pharmaceutical Research
基金 陈可冀中西医结合发展基金资助项目(No.CKJ2009009) 福建省高校中药学重点实验室开放课题基金资助项目(No.CKJ2007024ZYX200702) 福建省教育厅科技项目基金资助项目(No.JA07121)
关键词 血栓 血小板膜糖蛋白Ⅱb/Ⅲa 受体 拮抗剂 thrombosis platelet glycoprotein Ⅱb/Ⅲ a receptor antagonists
  • 相关文献

参考文献16

  • 1胡晓佳,杨宁.溶血栓药物近年来的研究进展[J].中国科技信息,2007(22):183-185. 被引量:8
  • 2Ruggeri ZM. Platelets in atherothrombosis[J]. Nat Med, 2002, 8(11) :1227 -1234.
  • 3Gachet C, Regulation of platelet functions by P2 receptors[ J]. Annu Rev Pharmacol Toxicol , 2006, 46:277-300.
  • 4Moroi M, Jung SM. Platelet glycoprotein Ⅵ: its structure and function[J]. Thromb Res, 2004, 114(4) :221 -233.
  • 5Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? [J]. Blood, 2003, 102(2) :449 -461.
  • 6Shattil SJ, Newman PJ. Integrins : dynamic scaffolds for adhesion and signaling in platelets [ J ]. Blood, 2004, 104 ( 6 ) : 1606 - 1615.
  • 7阮长耿.血小板膜糖蛋白与血栓性疾病[J].中国血液流变学杂志,2001,11(3):173-174. 被引量:13
  • 8郑秋甫.血小板糖蛋白Ⅱ_b/Ⅲ_a受体拮抗剂研究现状[J].中华老年心脑血管病杂志,2003,5(1):62-64. 被引量:3
  • 9Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins Ⅱb and/or Ⅲa[ J ]. Clin Invest,1983, 72 ( 1 ) :325 - 338.
  • 10Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial [J]. Circulation, 2003, 108(11) :1316 -1323.

二级参考文献42

  • 1路晓钦,张关印,高月.四物汤及其拆方对大鼠体外血小板聚集率的影响[J].中国中医药科技,2004,11(4):212-213. 被引量:5
  • 2董静懿,李培成.冠心病患者血小板CD62p及GpⅡb/Ⅲa的变化[J].检验医学,2005,20(3):189-191. 被引量:11
  • 3Coller BS. Blockade of platelet GP Ⅱb/Ⅲa receptor as an antithromboric strategy[J]. Circulation, 1995,92:2373-2380.
  • 4Chew DP, Molitemo DJ. A critical appraisal of platelet glycoprotein Ⅱb/Ⅲa. Inhibition[ J ]. JACC, 2000,36: 2028-2035.
  • 5Talley JD. Pharmacology of GP Ⅱb/Ⅲa platelet inhibition, part Ⅳ[J]. J of Interven Cardiol, 2000,13 : 243-254.
  • 6Lincoff AM, Califf RM,Topol El. Platelet glycoprotein Ⅱb/Ⅲa receptor blockade in coronary artery disease [ J ]. JACC, 2000,35 : 1103-1115.
  • 7The EPIC investigator. Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J]. N Engl J Med, 1994,330:956-961.
  • 8The EPILOG investigator: Platelet glycoprotein Ⅱb/Ⅲa receptor blockade and low-dose heparin during percutaneous coronary revascularization[J]. N Engl J Med, 1997,336:1689-1696.
  • 9The EPISTENT investigator(evaluation of platelet GP Ⅱb/Ⅲa inhibition for stenting). Randomized placebo-controlled and balloon-angioplasty-controUed trial to assess safety of coronary stenting with use to platelet glycoprotein Ⅱb/Ⅲa blockade[ J ]. Lancet, 1998,352: 87-92.
  • 10The CAPTURE investigator. Randomized placebo - controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study[ J]. Lancet, 1997,349:1429-1435.

共引文献52

同被引文献301

引证文献24

二级引证文献146

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部